publication venue for
- Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors 2007
- Macrolides and management of community-acquired pneumonia: A review of international guidelines 2004
- Effects of inhaled formoterol and budesonide in reducing asthma exacerbations 1998
- Concluding discussion 1998
- Delivery and the importance of the inhalation device in asthma therapy 1997
- Summary: The future promise of mediator inhibitors 1997
- Discussion 1996
- An overview of the cellular changes in pulmonary hypertension 1993
- Attenuation of pulmonary vascular remodelling by natriuretic peptides 1993
- Cyclic mechanical load and growth factors stimulate endothelial and smooth muscle cell DNA synthesis 1993
- Elastase activity and the pathophysiology of pulmonary hypertension 1993
- Elastin metabolism in the vessel wall during pulmonary hypertension 1993
- Endothelial cell derived growth factors in pulmonary vascular hypertension 1993
- Role of interstitial fibroblasts and intermediate cells in microvascular wall remodelling in pulmonary hypertension 1993
- The role of mechanical force in the regulation of fibroblast function: Implications for enhanced collagen deposition during pulmonary vascular remodelling 1993
- THE PATHOLOGY OF PULMONARY-HYPERTENSION 1993
- Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. 33:240015-240015. 2024
- Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. 32:220206-220206. 2023
- Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. 31:220036-220036. 2022
- European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. 30:210200-210200. 2021
- Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework. 30:210104-210104. 2021
- Guidance production before evidence generation for critical issues: the example of COVID-19. 29:200310-200310. 2020
- What have we learned from basic science studies on idiopathic pulmonary fibrosis?. 28:190029-190029. 2019
- Acute exacerbations of progressive-fibrosing interstitial lung diseases. 27:180071-180071. 2018
- Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. 27:180094-180094. 2018
- Matrix abnormalities in pulmonary fibrosis. 27:180033-180033. 2018
- Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. 24:356-360. 2015
- Staging of idiopathic pulmonary fibrosis: past, present and future. 23:220-224. 2014
- Fibrocytes in pulmonary fibrosis: a brief synopsis. 22:552-557. 2013
- The mechanisms of dyspnoea. 12:31-33. 2002
- Introduction. 7:251-252. 1997
- The natural history of asthma. 6:23-26. 1996
- What's new in mediators and mediator antagonists?. 4:399-402. 1994